global+growth

This international, cross-sectional survey was developed by investigators from a range of clinical practice settings across low-income to high-income countries, including members of the WHO Essential Medicines Cancer Working Group.

The U.N.-backed vaccine program is so far behind schedule that not even 10 percent of the population in poor countries is fully vaccinated, experts say.

The purchase was to be announced early next week to coincide with the United Nations General Assembly meeting in New York.

The drive to produce vaccines in Africa is designed to help more developing countries access COVID-19 shots after rich nations bought up most of this year's supply.

World Health Organization head Tedros Adhanom Ghebreyesus said at the same briefing that the continent was being "left behind by the rest of the world" and that this would allow the coronavirus to keep circulating.

The fight against Covid-19 is further fueling the greed of pharmaceutical companies. Does the industry’s influence threaten public health systems?

GSK’s Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from.

MSF calls on governments of high-burden countries to allow production of these lifesaving drugs to be affordable for all.

The doses are being delivered through COVAX, jointly run by the World Health Organization and the Global Alliance for Vaccines and Immunization (GAVI).

At the time the European Commission described it as a temporary agreement, while J&J had no comment when contacted by Reuters.

Bloc had come under fire for taking away shots from continent with lowest vaccination rate.

Health technologies are essential for a functioning health system.

Industrialized nations have already donated tens of millions of vaccine doses via the UN's COVAX vaccine program. But it's a slow process.

The Chinese shipments will help the sputtering global COVAX vaccine sharing programme which is far behind its pledge to deliver 2 billion doses this year following supply problems and export curbs imposed by major producer India.

Congress appropriated $16 billion to ramp up Covid-19 countermeasures, but a new report found that the Biden administration had spent very little of it on expanding vaccine manufacturing capacity.